1. Volume 150, Issue 2, Pages 299-306 (August 2016)
High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis 
Anna-Maria Hoffmann-Vold, MD, PhD, Anders Heiervang Tennøe, MD, Torhild Garen, Øyvind Midtvedt, MD, Aurelija Abraityte, Trond Mogens Aaløkken, MD, PhD, May Britt Lund, MD, PhD, Cathrine Brunborg, Pål Aukrust, MD, Prof, Thor Ueland, MD, Prof, Øyvind Molberg, MD, Prof 
CHEST 
Volume 150, Issue 2, Pages (August 2016)
DOI: /j.chest
Copyright © 2016 American College of Chest Physicians Terms and Conditions

2. Figure 1
Boxplot showing serum levels of CCL18 in patients with SSc and healthy control subjects. Broken line indicates the cutoff of 53 ng/mL. SSc = systemic sclerosis.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

3. Figure 2
FVC > 10% decline, FVC < 70% at follow-up, and survival in patients with SSc with short disease duration stratified by high (Red bars) and low (Blue bars) CCL18 serum levels. See Figure 1 legend for expansion of abbreviation.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

4. Figure 3
A, Cumulative survival of patients with systemic sclerosis stratified by CCL18 level. B, Cumulative survival of patients with systemic sclerosis with short disease duration stratified by CCL18 level. High (Blue lines) and low (Red lines) CCL18 levels are reported below the figure in ng/mL.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions